CD226 and neoplasm: DNAM-1 synergizes with other NK cell receptor ligands [including intercellular adhesion molecule-1 (ICAM-1), NKG2D-L, and CD48] to recognize CD155, thereby inducing NK cell cytotoxic responses that inhibit viral replication and control tumor burden [77].